Genmab A/S – NASDAQ:GMAB
Founder-led company
Genmab A/S stock price today
$23.82
+2.80
+13.32%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Genmab A/S stock price monthly change
-22.29%
month
Genmab A/S stock price quarterly change
-22.29%
quarter
Genmab A/S stock price yearly change
-33.82%
year
Genmab A/S key metrics
Market Cap | 13.11B |
Enterprise value | 16.16B |
P/E | 31.71 |
EV/Sales | 1.10 |
EV/EBITDA | 2.22 |
Price/Sales | 11.02 |
Price/Book | 5.86 |
PEG ratio | 0.38 |
EPS | 83.49 |
Revenue | 17.76B |
EBITDA | 6.72B |
Income | 5.45B |
Revenue Q/Q | 45.16% |
Revenue Y/Y | 15.87% |
Profit margin | 37.83% |
Oper. margin | 43.56% |
Gross margin | 0% |
EBIT margin | 43.56% |
EBITDA margin | 37.87% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGenmab A/S stock price history
Genmab A/S stock forecast
Genmab A/S financial statements
| Jun 2023 | 4.19B | 1.35B | 32.32% |
|---|---|---|---|
| Sep 2023 | 4.74B | 2.12B | 44.88% |
| Dec 2023 | 4.67B | 640M | 13.68% |
| Mar 2024 | 4.14B | 1.32B | 31.98% |
| Sep 2025 | 5.77B | 202.22M | 3.5% |
|---|---|---|---|
| Dec 2025 | 6.02B | 202.65M | 3.36% |
| Mar 2026 | 5.72B | 145.32M | 2.54% |
| Jun 2026 | 6.54B | 201.19M | 3.07% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-09 | 1.65 | 0.53 |
|---|---|---|
| 2023-02-22 | 0.2354 | 0.12 |
| Jun 2023 | 31978000000 | 3.22B | 10.08% |
|---|---|---|---|
| Sep 2023 | 35238000000 | 4.12B | 11.71% |
| Dec 2023 | 35289000000 | 3.67B | 10.43% |
| Mar 2024 | 36680000000 | 4.18B | 11.4% |
| Jun 2023 | 436M | -1.83B | 7M |
|---|---|---|---|
| Sep 2023 | 2.03B | 1.00B | 20M |
| Dec 2023 | 1.67B | -442M | -22M |
| Mar 2024 | 1.51B | -1.44B | -595M |
Genmab A/S alternative data
| Aug 2023 | 1,846 |
|---|---|
| Sep 2023 | 2,015 |
| Oct 2023 | 2,015 |
| Nov 2023 | 2,015 |
| Dec 2023 | 2,132 |
| Jan 2024 | 2,132 |
| Feb 2024 | 2,132 |
| Mar 2024 | 2,204 |
| Apr 2024 | 2,204 |
| May 2024 | 2,204 |
| Jun 2024 | 2,286 |
| Jul 2024 | 2,286 |
Genmab A/S other data
37.47%
-31.74%
of GMAB is owned by hedge funds
143
-85
24.73M
-20.97M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 17 Jul 2020 Issue date: 1 Sep 2022 |
Application Filling date: 10 Dec 2021 Issue date: 25 Aug 2022 |
Application Filling date: 14 Dec 2021 Issue date: 30 Jun 2022 |
Grant Utility: Humanized or chimeric CD3 antibodies Filling date: 14 Jul 2016 Issue date: 14 Jun 2022 |
Application Filling date: 16 Jun 2021 Issue date: 9 Jun 2022 |
Application Filling date: 7 Jul 2021 Issue date: 2 Jun 2022 |
Application Filling date: 22 Dec 2021 Issue date: 12 May 2022 |
Application Filling date: 14 Jun 2021 Issue date: 5 May 2022 |
Application BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA Filling date: 21 Dec 2021 Issue date: 21 Apr 2022 |
Application BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA Filling date: 22 Dec 2021 Issue date: 14 Apr 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Jan G.J. van de Winkel (1961) Co-Founder, Pres & Chief Executive Officer | $2,690,000 |
Mr. Anthony Mancini (1971) Executive Vice President & Chief Operating Officer | $1,390,000 |
| Dr. Judith V. Klimovsky (1958) Executive Vice President & Chief Devel. Officer | $1,090,000 |
Mr. Anthony Pagano (1978) Executive Vice President & Chief Financial Officer | $911,730 |
Mr. Peter Storm Kristensen (1975) Director of Legal Lead Corporation & Non-Independent Director | $60,780 |
Dr. Mijke Zachariasse Ph.D. (1974) Director of Protein Production & Chemist and Non-Independent Director | $60,780 |
Dr. Rima Bawarshi Nassar Ph.D. (1953) Vice President, Head of Global Regulatory Affairs  Oncology & Non-Independent Director | $15,200 |
Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology
Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
Genmab's Outlook Beyond Darzalex's Patent Cliff
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
PeptiDream: Opulent Dream Now A Reality
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)
Genmab: 3 Trends To Track For A Strong 2024 And Beyond
AbbVie Vs. GSK: Dual Dominance In Pharma
-
What's the price of Genmab A/S stock today?
One share of Genmab A/S stock can currently be purchased for approximately $23.82.
-
When is Genmab A/S's next earnings date?
Unfortunately, Genmab A/S's (GMAB) next earnings date is currently unknown.
-
Does Genmab A/S pay dividends?
No, Genmab A/S does not pay dividends.
-
How much money does Genmab A/S make?
Genmab A/S has a market capitalization of 13.11B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.87% to 16.47B US dollars. Genmab A/S earned 4.35B US dollars in net income (profit) last year or $0.12 on an earnings per share basis.
-
What is Genmab A/S's stock symbol?
Genmab A/S is traded on the NASDAQ under the ticker symbol "GMAB".
-
What is Genmab A/S's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Genmab A/S?
Shares of Genmab A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Genmab A/S's key executives?
Genmab A/S's management team includes the following people:
- Dr. Jan G.J. van de Winkel Co-Founder, Pres & Chief Executive Officer(age: 64, pay: $2,690,000)
- Mr. Anthony Mancini Executive Vice President & Chief Operating Officer(age: 54, pay: $1,390,000)
- Dr. Judith V. Klimovsky Executive Vice President & Chief Devel. Officer(age: 67, pay: $1,090,000)
- Mr. Anthony Pagano Executive Vice President & Chief Financial Officer(age: 47, pay: $911,730)
- Mr. Peter Storm Kristensen Director of Legal Lead Corporation & Non-Independent Director(age: 50, pay: $60,780)
- Dr. Mijke Zachariasse Ph.D. Director of Protein Production & Chemist and Non-Independent Director(age: 51, pay: $60,780)
- Dr. Rima Bawarshi Nassar Ph.D. Vice President, Head of Global Regulatory Affairs  Oncology & Non-Independent Director(age: 72, pay: $15,200)
-
Is Genmab A/S founder-led company?
Yes, Genmab A/S is a company led by its founder Dr. Jan G.J. van de Winkel.
-
How many employees does Genmab A/S have?
As Jul 2024, Genmab A/S employs 2,286 workers, which is 4% more then previous quarter.
-
When Genmab A/S went public?
Genmab A/S is publicly traded company for more then 16 years since IPO on 1 Jun 2009.
-
What is Genmab A/S's official website?
The official website for Genmab A/S is genmab.com.
-
How can i contact Genmab A/S?
Genmab A/S can be reached via phone at +45 70 20 27 28.
Genmab A/S company profile:
Genmab A/S
genmab.comExchange:
NASDAQ
Full time employees:
2,635
Industry:
Biotechnology
Sector:
Healthcare
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Kalvebod Brygge 43
Copenhagen, 1560
Copenhagen, 1560
CIK: 0001434265
ISIN: US3723032062
CUSIP: 372303206
